Background: Eosinophils play an important role in allergic responses. Eotaxin is a CC chemokine that promotes the selective recruitment of eosinophils. This study was performed to investigate the signiˆcance of eotaxin in pediatric food allergies.
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Introduction
Food allergies (FA) are common, with up to 8 of children under 3 years of age and around 2 of adults experiencing allergic reactions to food 1) . Although IgE is commonly used as a clinical marker of allergy, this class of antibody does not always re‰ect the allergic status accurately, because allergic symptoms involve the activation of both IgE-and non-IgE-mediated pathways 2, 3) . Eosinophils, CD4 ＋ T cells, and mast cells play important roles in allergic responses 4) . In particular, eosinophils include a variety of proin‰ammatory mediators that can contribute to allergic reactions 5) and accumulate in the foci of allergic responses. Eosinophils normally account for only a small percentage of circulating or tissue-dwelling cells, and their numbers are increased markedly in allergic diseases. Numerous mediators have been identiˆed as eosinophil chemoattractants, including lipid mediators (platelet-activating factor, leukotrienes), bacterial products (formyl-methionylleucyl-phenylalanine), and chemokines (regulated on activation, normal T cells expressed and secreted, and macrophage in‰ammatory protein 1). However, none of these mediators selectively promote eosinophil recruitment. Therefore, they are unlikely to be the primary mediators of the tissue eosinophilia observed in numerous hypereosinophilic disorders.
Eotaxin 1/CCL11, eotaxin 2/CCL24 and eotaxin 3/CCL26 are CC chemokines that promote the recruitment of eosinophils 6～8) . The eotaxins act via interaction with a speciˆc receptor, CCR3, which is expressed mainly on eosinophils 9) . In addition to eosinophils, basophils express CCR3 and migrate toward eotaxin 10) . Although Th2 cells have also been shown to express CCR3, it is controversial 11) . Previous studies showed that plasma eotaxin levels in allergic patients with bronchial asthma and atopic dermatitis are higher than those in normal controls 12, 13) . However, little is known about the correlations among eotaxin group levels, eosinophil counts, and IgE levels in patients with FA. In the present study, we showed that levels of eotaxin 1, but not eotaxin 3, were signiˆcantly elevated in FA, and discuss the role of eotaxins in this condition. 
Subjects and methods

Subjects
The study population consisted of 35 patients with food allergy (FA) and 18 patients with atopic dermatitis (AD) but without FA (Table) . The FA group included 18 patients with and 17 patients without AD. Therefore, the AD group consisted of a total of 36 patients, including 18 with and 18 without FA. The patients with FA showed food-mediated acute allergic reactions above grade 2 14) including anaphylaxis and/ or urticaria. The clinical diagnoses were based on a careful history, laboratoryˆndings (total and speciˆc IgE), dietary elimination tests, and food challenge tests. Of the 35 FA patients, 25 underwent food elimination treatment. Speciˆc IgE values against food antigens were scored as 3 or more in all patients. The control group consisted of 19 disease-free children without allergy. Subjects with fever, diarrhea, infectious diseases, or other chronic diseases were excluded. The diŠerences in age were not signiˆcant among FA patients (mean±SD: 2.5±2.0 years), AD patients (2.5±1.9 years), and controls (2.9±1.9 years). Informed consent was obtained from caregivers of the patients and controls before enrollment in this study.
Measurements
Blood samples were harvested in tubes containing EDTA by venous puncture. Plasma specimens were separated and stored at -30°C. Hemolyzed samples were avoided. Concentrations of both eotaxin 1 and eotaxin 3 were measured by enzyme-linked immunosorbent assay (ELISA) (Quantikine; R&D Systems, Minneapolis, MN). The limits of detection were 5 pg/ml for eotaxin 1 and 0.87 pg/ml for eotaxin 3. Speciˆc IgE levels were measured using the Phadea CAP System FEIA (formerly Pharmacia & Upjohn AB Diagnostics, Uppsala, Sweden).
Statistical analysis
Data are expressed as means±SD. The results were analyzed using a commercially available computer software package (Stat View; Abacus Concepts Inc, Berkley, CA). The signiˆcance of diŠerences between two independent groups was determined using the Mann-Whitney U test. Relationships between plasma eotaxin levels and other indices were assessed based on the Pearson correlation coe‹cients. DiŠerences were considered signiˆcant at P＜0.05.
Results
Samples were collected from 35 FA patients, 18 AD patients without FA, and 19 disease-free controls. As indicated in the Table, FA patients had signiˆcantly larger numbers of circulating eosinophils than the controls (5.84±9.46×10 9 /l vs. 1.20±1.11×10 9 /l, P ＜0.001). Serum IgE levels in FA patients were higher than those of the controls (1007±1315 U/ml vs. 16± 18 U/ml, P＜0.001). Eosinophil counts (7.04±8.42 ×10 9 /l, P＜0.001) and IgE levels (878±1843 U/ml, P＝0.005) in AD patients without FA were higher than those of the controls. In contrast, there were no signiˆcant diŠerences between FA and AD patients without FA in IgE levels (P＝0.119) or eosinophil counts (P＝0.505).
As shown in Fig. 1 , plasma eotaxin 1 levels in FA patients (93.6±33.4 pg/ml, 46.0 200.3 pg/ml, n＝ 35) were signiˆcantly higher than those of the controls (60.4±15.7 pg/ml, 35.3 91.3 pg/ml) (P＜ 0.001). The diŠerence between plasma eotaxin 3 levels in FA patients (2.0±3.2 pg/ml, 0.1 18.1 pg/ml) and the controls (1.4±1.1 pg/ml, 0.1 3.4 pg/ml) was not signiˆcant (P＝0.978), although a small number of FA patients had high eotaixn 3 levels.
In previous study 12) , AD subjects did not exclude those with FA. To obtain comparable results,ˆrst we analyzed AD subjects both with FA and without FA. Figure 1 shows that eotaxin 1 levels were signiˆcantly higher in AD patients (84.3±31.1 pg/ml, 40.7 163.0 pg/ml, n＝36) than in controls (P＝0.003). In contrast, eotaxin 3 levels in AD patients (2.1±3.4 pg/ ml, 0.1 18.1 pg/ml) were not signiˆcantly diŠerent from those of controls (P＝0.951). There were no signiˆcant diŠerences in eotaxin 1 (P＝0.223) or eotaxin 3 levels (P＝0.850) between FA patients and AD patients.
Half of the patients with FA also had AD ( Table  1) . To determine whether the elevated levels of plasma eotaxin 1 in the FA patients re‰ect the status of AD, we then divided the FA group into subjects with and without AD, and repeated the analysis for AD subjects without FA only, as shown in Fig. 2 . Eotaxin 1 levels not only in FA patients with AD (FA＋/ AD＋, 90.7±29.8 pg/ml, n＝18) but also in FA patients without AD (FA＋/AD , 96.6±37.5 pg/ml, n＝17) were signiˆcantly higher than those of the controls (P＜0.001). Eotaxin 3 levels were not signiˆcantly diŠerent among FA＋/AD＋ (2.4±4.1 pg/ ml), FA＋/AD (1.7±2.1 pg/ml), and controls.
There was no signiˆcant diŠerence in eotaxin 1 level between AD patients without FA (FA /AD＋, 78.0 ±31.8 pg/ml, n＝18) and the controls (P＝0.081). Eotaxin 3 levels were not signiˆcantly diŠerent between FA /AD＋ (1.9±2.8 pg/ml) and the controls (P＝0.616). Neither eotaxin 1 nor eotaxin 3 levels were signiˆcantly diŠerent between FA＋/AD＋ and FA /AD＋ (P＝0.092 and P＝0.704, respectively). In addition, diŠerences in eotaxin 1 and eotaxin 3 levels were not signiˆcant between FA subgroups with and without AD (P＝0.817 and P＝0.255, respectively).
The correlations among eotaxins, eosinophils, and IgE were examined. The correlations between eotaxin 1 and eotaxin 3 were not signiˆcant in FA (r＝ 0.018, P＝0.918) or the controls (r＝0.413, P＝ 0.079). In FA patients, there were no signiˆcant correlations between either eotaxin 1(r＝ 0.024, P＝ 0.892) or eotaxin 3 (r＝ 0.014, P＝0.935) and circulating eosinophil counts. In the controls, no signiˆcant correlation was found between either eotaxin 1 (r＝ 0.263, P＝0.281) or eotaxin 3 (r＝0.236, P＝0.336) and eosinophil counts. The results were similar between both eotaxin 1 (r＝ 0.176, P＝ 0.314) and eotaxin 3 (r＝0.265, P＝0.125) and IgE in the FA patients. Consistent results were observed in the controls (eotaxin 1 and IgE, r＝ 0.368, P＝ 0.149; eotaxin 3 and IgE, r＝ 0.071, P＝0.791).
Fig. 2 Eotaxin 1 (A) and eotaxin 3 (B) levels in plasma of
patients with food allergy (FA) and atopic dermatitis (AD). To determine whether elevated levels of plasma eotaxin 1 in the FA patients re‰ect the status of AD, the FA group was divided into subjects with (FA＋/ AD＋, n＝17) and without AD (FA＋/AD , n＝18), and compared with AD subjects only without FA (FA /AD＋, n＝18). Eotaxin 1 levels in FA＋/AD＋ and FA＋/ADwere signiˆcantly higher than those of the controls. Eotaxin 1 levels in FA /AD＋ were not signiˆcantly diŠerent from FA＋/AD＋ or disease-free controls. Finally, the eŠects of food elimination treatment on eotaxin levels were analyzed in food allergy patients. There were no signiˆcant diŠerences in eotaxin 1 levels in subjects with (94.0±30.1 pg/ml, n＝25) or without food elimination treatment (92.5 ±42.3 pg/ml, n＝10, P＝0.635) (Fig. 3) . Similar results were observed for eotaxin 3 in subjects with (2.2±3.7 pg/ml) and without food elimination treatment (1.7±1.5 pg/ml, P＝0.743).
Discussion
In the present study, plasma eotaxin 1 levels were signiˆcantly elevated in patients with FA compared to the values in disease-free controls. Increases in eotaxin 1 levels have also been reported in bronchoalveolar lavage ‰uid 15) and sputum 16, 17) from asthmatics, human milk in allergic mothers 18) , and skin biopsy specimens from AD patients 19) . Recently, Fulkerson et al. demonstrated that chronic allergic airway in‰ammation was impaired in mice with defects in eosinophils, CCR3 knockout mice, and mice deˆcient in both eotaxin 1 and eotaxin 2 20) . They concluded that eosinophils play a central role in chronic allergic airway disease via CCR3 20) . These lines of evidence suggest a crucial role of eotaxin 1 in the pathogenesis of allergic disorders.
Previous studies showed increases in eotaxin 1 levels in AD patients 12, 21, 22) , as observed in the present study in AD patients with FA and without FA. Our FA group, which included both patients with and without AD, showed increased levels of eotaxin 1. This suggested the possibility that only the AD patients among our FA patients contributed to the elevation of eotaxin 1. To determine whether our observations were due to the AD patients, the FA subjects were divided into an AD group and a non AD group. Eotaxin 1 levels were signiˆcantly higher in not only in FA patients with AD but also in those without AD than in controls. There was no signiˆcant diŠerence in eotaxin 1 level between the AD and non AD groups in FA patients. In addition, eotaxin 1 levels in AD subjects without FA were not signiˆcantly diŠerent from FA patients with AD or disease-free controls. These results indicated that eotaxin 1 levels are increased in FA patients regardless of AD.
In the present study, there were no signiˆcant diŠerences in eotaxin 3 level among the FA group, AD group, and disease-free controls. In contrast, Berkman et al. reported that baseline eotaxin 3 mRNA expression was not increased in asthmatic patients in comparison with control subjects, but was markedly enhanced 24°h after allergen challenge in asthmatic patients 23) . Kagami et al. suggested that serum levels of eotaxin 3 were closely correlated with disease activity of AD 24) . Poltzer et al. showed that eotaxin 3, in contrast to eotaxin 1 and eotaxin 2, was elevated in serum samples of patients with active Churg?Strauss Syndrome, characterized by eosinophilia and granulomatous vasculitis 25) . They further reported that eotaxins were not elevated in other eosinophilic diseases 25) . Allergen-induced eosinophil recruitment into the airway was abolished in mice deˆcient in both eotaxin 1 and eotaxin 2 as well as in CCR3 deˆcient mice 20) . Taken together, these observations indicate that the association between eotaxin 3 and eosinophil-induced allergic in‰ammation is not strong. Further studies of eotaxin 3 in FA are required.
There were no correlations between plasma eotaxins and circulating eosinophil counts in FA patients or controls. Theseˆndings may be related to the hypothesis of Rothenberg et al. 10) that eotaxin plays an important role in the maintenance of basal levels of circulating eosinophils. Given the ability of eotaxins 1 to recruit eosinophils into the tissues and to activate the proin‰ammatory eŠector functions of the cells 20) , eotaxin 1 may be a candidate pathogenic molecule in FA.
In the present study, food elimination treatment did not signiˆcantly aŠect plasma levels of eotaxin 1 or eotaxin 3. It is di‹cult to avoid all antigens, including minor antigens, in the clinical treatment of FA. It is possible that minor antigens could stimulate allergic in‰ammation, and still result in high levels of plasma eotaxin 1. To elucidate the precise role of eotaxin 1 in food elimination for FA, a strict prospective study is required.
In summary, the results of the present retrospective study suggested that levels of plasma eotaxin 1 are elevated in food allergy. Eotaxin 1 may be a useful parameter to assess this disorder.
